The Ministry of Health in Norway has ordered its four regional health authorities to offer medicine-free treatment in psychiatric hospitals. A six-bed ward in Tromso, which is in the far north of Norway, is now providing such care.
The American Psychiatric Association and its former president, Jeffrey Lieberman, have used the Goldwater Rule to try to silence Yale psychiatrist Bandy Lee and colleagues who warned, in a collection of essays, about why President Trump is "dangerous." Why would a guild choose to do this?
Lancet Psychiatry, a UK-based medical journal, recently published a study that concluded brain scans showed that individuals diagnosed with ADHD had smaller brains. That conclusion is belied by the study data. The journal needs to retract this study. UPDATE: Lancet Psychiatry (online) has published letters critical of the study, and the authors' response, and a correction.
Jeffrey LIeberman and colleagues have published a paper in the American Journal of Psychiatry stating that there is no evidence that psychiatric drugs cause long-term harm, and that the evidence shows that these drugs provide a great benefit to patients. A close examination of their review reveals that it is a classic example of institutional corruption, which was meant to protect guild interests.
After a meta-analysis of RCTs of antidepressants was published in Lancet, psychiatry stated that it proved that "antidepressants" work. However, effectiveness studies of real-world patients reveal the opposite: the medications increase the likelihood that patients will become chronically depressed, and disabled by the disorder.
During the past twenty years, the American Foundation for Suicide Prevention and American psychiatry have adopted a "medicalized" approach to preventing suicide, claiming that antidepressants are protective against suicide. Yet, the suicide rate in the United States has increased 30% since 2000, a time of rising usage of antidepressants. A review of studies of the effects of mental health treatment and antidepressants on suicide reveals why this medicalized approach has not only failed, but pushed suicide rates higher.
At the Hurdalsjøen Recovery Center in Norway, patients with a long history of psychiatric hospitalizations are tapering from their medications and, in a therapeutic environment that emphasizes a good diet, exercise, and asking patients "what do they want in life," are leaving their old lives as chronic patients behind.
The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.
In a MIA survey of people who had been patients in mental hospitals, nearly 500 respondents told of an experience that was often traumatic, and frequently characterized by a violation of their legal rights, forced treatment with drugs, and physical or sexual abuse. Only 17% said they were “satisfied” with the “quality of the psychiatric treatment” they received.
Hundreds of people have been given remote control deep brain stimulation implants for psychiatric disorders such as depression, OCD and Tourette’s. Yet DBS specialists still have no clue about its mechanisms of action and research suggests its hefty health and safety risks far outweigh benefits.
When Carina Håkansson sent out an invitation for a symposium on "Pharmaceuticals: Risks and Alternatives," some of the world's top scientists, along with experts-by-experience, came from 13 countries to explore better ways to respond to people in crisis.
A common refrain from the pro-forced treatment advocates at the summit was that "four walls" are not the solution to the crisis. Dr. Drew slammed such efforts in California during his presentation: "The vast majority have serious mental illness and drug addiction. Four walls are not going to do anything, if they would even go in."
This review of the scientific literature, stretching across six decades, makes the case that antipsychotics, over the long-term, do more harm than good. The drugs lower recovery rates and worsen functional outcomes over longer periods of time.
In 2008, a reviewer of psychiatric drugs at the FDA, Ron Kavanagh, complained to Congress that the FDA was approving a new antipsychotic that was ineffective and yet had adverse effects that increased the risk of death. Twelve years later, a review of the whistleblower documents reveal an FDA approval process that can lead to the marketing of drugs sure to harm public health.
MIA's Zenobia Morrill interviews Lucy Johnstone about the reaction to the Power Threat Meaning Framework, her life influences, and her hopes for the future.
The New Yorker's story on Laura Delano and psychiatric drug withdrawal is a glass-half-full story: It addresses a problem in psychiatry and yet hides the deeper story to be told. A story of how her recovery resulted from seeing herself within a counter-narrative that tells of the harm that psychiatry can do.
The ACE study tells of how adverse childhood experiences increase the risk of psychological and physical problems in adulthood. When will we start incorporating these findings into public health policy and medical care?
In Israel, there is a budding Soteria movement that foretells of a possible paradigm shift in care. The thought is that such care may become a first-line treatment for newly psychotic patients.
After 18 years, the full story of the scientific corruption in a study of paroxetine for bipolar disorder, and the psychiatrist who blew the whistle.
MIA’s Ayurdhi Dhar interviews Sunil Bhatia about decolonizing psychology, confronting the field’s racist past, colonial foundations, and neoliberal present.
For the past 15 years, the VA's suicide prevention efforts have focused on getting veterans screened and treated for psychiatric disorders, with antidepressants a first-line therapy. This effort has caused veteran suicide rates to steadily rise.
Peer-Support Groups Were Right, Guidelines Were Wrong: Dr. Mark Horowitz on Tapering Off Antidepressants
In an interview with MIA, Dr. Horowitz discusses his recent article on why tapering off antidepressants can take months or even years.
The proponents of compulsory outpatient treatment claim that it leads to better outcomes for the recipients, and protects society from violent acts by the "seriously mentally ill." Those claims are belied by history, science, and a critical review of the relevant research.
Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.
MIA’s Ayurdhi Dhar interviews Ian Parker about critical psychology, discourse and political action, and whether psychology has anything left to offer.